Juan José Salazar-González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Juan José Salazar-González has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anna Aulinas
Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic/Manresa , 08500 Catalonia
1 shared publication - Iñaki Argüelles
Endocrinology and Nutrition Department, Son Espases University Hospital, Palma, Spain
1 shared publication - Javier Bodoque Cubas
Institut d’Investigació Sanitària Pere Virgili, Tarragona, Spain
1 shared publication - José Fernández-Sáez
Servei Atenció Primària Terres de l’Ebre, Institut Català de la Salut, 43500 Tortosa, Tarragona, Spain
1 shared publication - José Vicente Gil-Boix
Faculty of Medicine, Universitat Jaume I, Castellón de la Plana, Valencian Community, Spain
1 shared publication - Marcel·lA Miret-Llauradó
Rovira i Virgili University, Faculty of Medicine, PhD School of Biomedical Sciences , Tarragona, Catalonia 43002
1 shared publication
Latest Publications
- 12 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 405-417
Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis
Objective: The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN. Methods: A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness. Results: KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy. Conclusion: KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.
- 12 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , 405-417
Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis
Objective: The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN. Methods: A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness. Results: KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy. Conclusion: KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.